To reduce its reliance on Enhertu ahead of the cancer treatment's patent expiry, Daiichi Sankyo is betting on a new wave of antibody-drug conjugates to expand its oncology business. japantimes.co.jp/business/2026… #business #companies #daiichisankyo #health #pharmaceuticals #medicine #patents